22 October 2025
: Case report 
Refractory Renovascular Hypertension from Paraganglioma: A Case Report
Mistake in diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology
Ayako Shimizu ABEF 1, Kota Kakeshita
ABEF 1, Teruhiko Imamura AEF 1*, Sayaka Murai BE 1, Hidenori Yamazaki E 1, Hiroshi Ueno BE 1, Tsutomu Koike ABEF 1, Koichiro Kinugawa AE 1
DOI: 10.12659/AJCR.949663
Am J Case Rep 2025; 26:e949663
Table 2 Endocrinological findings during the clinical course.
| Reference ranges | Before the first PTRA (at age 24) | After the first PTRA (at age 24) | Before the second PTRA (at age 33) | After the second PTRA (at age 33) | 1 year after surgical resection (at age 35) | |
|---|---|---|---|---|---|---|
| Plasma renin activity, ng/mL/hour | 0.2–2.3 | 3.4 | 1.2 | 8.7 | 2.4 | 1.7 |
| Plasma aldosterone, pg/mL* | 29.9–159 | 19.7 | 6.3 | 293 | 89 | 363 |
| Plasma adrenaline, pg/mL | 0–100 | 52 | 22 | 20 | ||
| Plasma noradrenaline, pg/mL | 100–450 | 1,393 | 2,152 | 234 | ||
| Plasma dopamine, pg/mL | 0–20 | 38 | 12 | 11 | ||
| Urine metanephrine, ng/mg of Cr | 4–190 | 137 | 94 | |||
| Urine normetanephrine, ng/mg of Cr | 9–330 | 1,204 | 189 | |||
| * Plasma aldosterone concentration was measured by radioimmunoassay. PTRA – percutaneous transluminal renal angioplasty; Cr – creatinine. | ||||||